Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026)

Coherus Oncology has disclosed Net Cash Flow across 14 years of filings, most recently posting -$32.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 124.03% year-over-year to -$32.3 million; the TTM figure through Jun 2026 stood at -$134.0 million (down 333.18% YoY), while the FY2025 annual figure was -$37.1 million, down 262.09% from the prior year.
• Net Cash Flow came in at -$32.3 million for Q2 2026 at Coherus Oncology, down from $26.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $156.9 million in Q1 2024 to a low of -$223.3 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$18.6 million, with a median of -$23.4 million recorded in 2025.
• The largest YoY upside for Net Cash Flow was 430.96% in 2024 against a maximum downside of 939.87% in 2024.
• Over 5 years, Net Cash Flow stood at -$223.3 million in 2022, then jumped by 110.14% to $22.6 million in 2023, then advanced by 25.03% to $28.3 million in 2024, then plunged by 151.15% to -$14.5 million in 2025, then slumped by 123.28% to -$32.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$32.3 million in Q2 2026, $26.4 million in Q1 2026, and -$14.5 million in Q4 2025.